Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01162681 · ClinicalTrials.gov registry record · Phase 2
PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Anthera Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 547
- Enrollment target
NCT01162681: Completed Phase 2 study, sponsored by Anthera Pharmaceuticals.
NCT01162681 is a Phase 2 study that has completed, run by Anthera Pharmaceuticals. The registered enrollment target is 547 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (311% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01162681, a Phase 2 study, has completed, sponsored by Anthera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 547 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of three different doses of A-623 administered in addition to standard therapy in subjects with active SLE disease
Primary Outcome
The % of subjects with SLE response compared with baseline at the time of assessment
Interventions
- OTHER Placebo Comparator
- DRUG A-623
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 547 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
What the finished NCT01162681 record still lists
NCT01162681 is an interventional study that assigns participants to a tested intervention. The registered 547 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (311% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT01162681 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01162681 about?
NCT01162681 is a clinical study titled "PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus". The purpose of this study is to evaluate the efficacy, safety and tolerability of three different doses of A-623 administered in addition to standard therapy in subjects with active SLE disease
What is the current status of trial NCT01162681?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 547 participants. The study started on 2010-07. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01162681?
The interventions under investigation include: Placebo Comparator (OTHER), A-623 (DRUG).
Who is sponsoring clinical trial NCT01162681?
This trial is sponsored by Anthera Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01162681's enrollment target sits among peer trials
547 62nd of 2000 higher than 1,939 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03572374 · 546 participants · NA
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
- NCT05937685 · 546 participants · NA
Reducing Blood Pressure in Patients With High Cardiovascular Risk
- NCT06416150 · 546 participants · NA
Reducing Urban Cervical Cancer Disparities
- NCT06850922 · 546 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia